MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer | Zendy

Tao Xie | Zendy; Mengxi Huang | Zendy; Ye Wang | Zendy; Liya Wang | Zendy; Cheng Chen | Zendy; Xiaoyuan Chu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer

Author(s) -

Tao Xie,

Mengxi Huang,

Ye Wang,

Liya Wang,

Cheng Chen,

Xiaoyuan Chu

Publication year - 2016

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000452525

Subject(s) - colorectal cancer , oxaliplatin , microrna , drug resistance , medicine , drug , cancer , bioinformatics , cancer research , oncology , pharmacology , biology , gene , genetics

Chemotherapy and targeted therapy are the main options for andvanced colorectal cancer (CRC). However, resistance to these therapies is a major challenge in the clinic. Understanding molecular mechanisms and developing effective strategies against the drug resistance are highly desired. Increasing evidence has revealed that microRNAs (miRNAs) are closely linked to drug resistance in CRC. The explosion of knowledge in this field has brought forward new predictive and therapeutic opportunities. In this review, we systemically summarize the roles of miRNAs as regulators, tissue or circulating biomarkers, and therapeutics in the CRC resistance to 5-fluorouracil (5-FU), oxaliplatin and anti-EGFR therapy. We also discuss the potential unsettled issues and future directions concerning these processes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research